Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2113436 | Cancer Letters | 2012 | 8 Pages |
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1). ABT-737, a small molecule inhibitor of Bcl-2, Bcl-XL, and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. Moreover, ABT-737 significantly inhibited the in vivo tumor growth of an ATLL mouse model. These results suggest that the use of an agent targeting anti-apoptotic bcl-2 family proteins, either alone or in combination with other conventional drugs, represents a novel promising approach for ATLL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kenji Ishitsuka, Naoko Kunami, Hiroo Katsuya, Rumiko Nogami, Chie Ishikawa, Fusanori Yotsumoto, Hiroe Tanji, Naoki Mori, Morishige Takeshita, Shingo Miyamoto, Kazuo Tamura,